Evaluation of Reproducibility in Urology Publications

Shelby Lynn Rauh, MS¹, Bradley S. Johnson, MA¹, Aaron Bowers BS¹, Daniel Tritz, MS¹,

Benjamin Matthew Vassar, PhD¹

¹Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.

Corresponding Author: Mrs. Shelby Lynn Rauh, Oklahoma State University Center for Health

Sciences, 1111 W 17th St., Tulsa, OK 74107, USA; email: shelby.rauh@okstate.edu

Conflicts of Interest and Source of Funding: This study was funded through the 2019

Presidential Research Fellowship Mentor–Mentee Program at Oklahoma State University Center

for Health Sciences.

Keywords: Cross-Sectional, Reproducibility, Urology

Take Home Message (17/40 words): Many components of transparency and reproducibility are lacking in urology publications, making study replication, at best, difficult.

Introduction: Reproducibility is essential for the integrity of scientific research. Reproducibility is measured by the ability of investigators to replicate the outcomes of an original publication by using the same materials and procedures.

Methods: We sampled 300 publications in the field of urology for assessment of multiple indicators of reproducibility, including material availability, raw data availability, analysis script availability, pre-registration information, links to protocols, and whether the publication was freely available to the public. Publications were also assessed for statements about conflicts of interest and funding sources.

Results: Of the 300 sample publications, 171 contained empirical data and could be analyzed for reproducibility. Of the analyzed articles, 0.58% (1/171) provided links to protocols, and none of the studies provided analysis scripts. Additionally, 95.91% (164/171) did not provide accessible raw data, 97.53% (158/162) did not provide accessible materials, and 95.32% (163/171) did not state they were pre-registered.

Conclusion: Current urology research does not consistently provide the components needed to reproduce original studies. Collaborative efforts from investigators and journal editors are needed to improve research quality, while minimizing waste and patient risk.

Introduction

Reproducibility is determined by the availability of materials, raw data, analysis procedures, and protocols used to conduct original research so that other researchers may replicate the findings; it is crucial to establishing credible and reliable research that ultimately governs clinical practice. Recent evidence suggests that up to 90% of preclinical research may not be reproducible.[1] A recent survey of over 1500 researchers concurred with this assessment, with the vast majority believing that biomedical research is experiencing a “reproducibility crisis”.[2] Several explanations have been offered for why reproducibility has become an issue, with pressure to publish and the race to be the first to report new findings being among the most likely causes.[3] When research is not reproducible, time and money are wasted reproducing erroneous results, and patients may be exposed to ineffective or harmful therapies.[4] Concerns about reproducibility span from preclinical to clinical research.

The field of prostate cancer research serves as an example. On the diagnostic side, *in vitro* studies are performed on prostate biopsy samples to advance understanding of early detection and diagnosis. However, widespread misuse of immunohistochemical staining exists, which contributes to the lack of research reproducibility. Sfanos *et al* [5] argued that the ubiquitously used research-grade antibodies within the biomedical research community (as opposed to clinical grade used for patient diagnosis) are not routinely validated in the investigators’ laboratories, which may lead to variable results that cannot be reproduced in subsequent studies. On the other end of the research spectrum, randomized clinical trials are conducted to evaluate the efficacy of new therapeutic agents for prevention or treatment of prostate cancer. In one large-scale randomized trial, Thompson *et al* [6] compared the effects of finasteride against placebo for

prostate cancer prevention. These investigators found that finasteride prevented or delayed the development of prostate cancer but also led to an increased risk of higher-grade cancer upon detection. The raw data from this clinical trial were not made entirely available because of patient privacy and data “messiness”. Some investigators attempted to reanalyze the trial data, but the results were mixed[7,8]. Since then, Baker *et al*[9] proposed a method to overcome issues of privacy and messiness, while also fostering reproducibility of the trial outcomes.

Thus, when a study does not report the components needed to reproduce it, or when studies are not replicated by other researchers, determining the credibility of the original findings is hindered. Our study examines existing research in urology and determines how often studies include markers of reproducibility and how frequently studies are replicated. This research highlights the issue of reproducibility in urology, a field in which the topic has not been well explored. We anticipate that our findings will prompt discussions among investigators and journal editors, which may lead to improvement in the quality of research in the field.

Methods

We used an observational, cross-sectional study design, drawing on the methodology of Hardwicke *et al*[10], with modifications. This study did not involve human participants and was not subject to oversight or approval by an institutional review board.[11] We report our study in accordance with previously published guidelines for meta-epidemiological methodology research.[12] To foster transparency and reproducibility, we have uploaded our protocol, data extraction form, and other materials for public viewing on the Open Science Framework (OSF; <https://osf.io/n4yh5/>).

Journal Selection

We used the National Library of Medicine (NLM) catalog to search for all relevant journals, using the subject terms tag Urology[ST]. The search was performed on 30 May 2019. The inclusion criteria required journals to have full-text publications in English and be MEDLINE indexed. The list of journals in the NLM catalog fitting the inclusion criteria were then extracted using the electronic International Standard Serial Number (ISSN) or the linking ISSN when the electronic ISSN was unavailable. PubMed was searched with the list of ISSNs to identify all articles published from 1 January 2014 to 31 December 2018. We randomly sampled 300 publications that met the inclusion criteria (<https://osf.io/csf5t/>).

Data Extraction Training

The two investigators responsible for data extraction (S.R. and B.J.) underwent a full day of training to ensure adequate interrater reliability. The training included an in-person session to review the project study design, protocol, data extraction form, and examples of where information may be contained using two example publications. The investigators were then given three example publications from which to extract data in a blinded fashion. Afterward, the pair reconciled differences in their results. This training session was recorded from the presenter's point of view (D.T.) and listed online for reference (<https://osf.io/tf7nw/>). As a final training exercise, investigators extracted data from the first 10 publications of the full sample and then met to reconcile any differences in the data before proceeding to extraction of the remaining 290 publications.

Data Extraction

Data extraction on the remaining 290 publications was conducted in a duplicate, blinded fashion. A final consensus meeting was held with both investigators to resolve disagreements. A third investigator (D.T.) was available for adjudication but was not needed. Data were extracted using a pilot-tested Google form based on Hardwicke *et al*, with modifications.[10] This form contained information necessary for a study to be reproducible, such as the availability of materials, data, protocols, or analysis scripts (<https://osf.io/3nfa5/>). The data extracted varied based on the study design, with studies having no empirical data being excluded (e.g., editorials, commentaries [without reanalysis], simulations, news, reviews, and poems) (Table 1). The form also included the 5-year impact factor and that of the most recent year available and expanded the study design options to include cohort studies, case series, secondary analyses, chart reviews, and cross-sectional studies. Funding options were also expanded to include university, hospital, public, private/industry, non-profit, or mixed funding.

Evaluation of Open Access Status

We evaluated all 300 publications to determine whether they were freely available online through open access. We searched Open Access Button (openaccessbutton.org) with publication titles and DOI numbers. This tool actively searches for the full-text online. If it could not find a publication, two of us (S.R. and B.J.) searched Google Scholar and PubMed to determine if the full text was available via open access on the journal website.

Evaluation of Replication and Whether Publications Were Included in Research Synthesis

For empirical studies, excluding meta-analysis and commentary with analysis, we searched the Web of Science to determine whether the publication was cited in a replication study, meta-analysis, or systematic review. The Web of Science additionally lists information important for our study, such as the country of journal publication, 5-year impact factor (when available), and most recent impact factor.

Statistical Analysis

We report descriptive statistics for each of our findings with 95% confidence intervals (95% CIs) using analysis functions within Microsoft Excel.

Results

Included Sample and Characteristics

Our inclusion criteria resulted in 42,422 articles from 46 urology journals found in the NLM catalog. Of the articles meeting the inclusion criteria, 300 articles were randomly chosen for analysis. Six articles were not analyzed because we did not have access to the text. The remaining 294 articles were assessed to determine the 5-year impact factor of their corresponding journals. Twenty of the 294 articles came from journals without 5-year impact factors. Thus, journals of the 274 studies reported a median of 2.466 as their 5-year impact factor with an interquartile range of 1.898 to 4.925. In addition, a full assessment of the original 300 articles revealed that 88 (29.33%) were accessible through Open Access Button or other means. Over half of our included studies (163/294, 55.44%) provided a statement revealing that their study was without a conflict of interest. However, 95 (32.31%) of our included studies did not provide any type of conflict of interest statement. Nearly two-thirds of our studies (185, 62.93%)

did not state if or from where they received funding. Among the 109 studies that provided a statement, most did not receive funding (31, 28.44%). Of the 78 studies that did receive funding, most obtained it through public entities (23, 29.49%). Other characteristics of our included studies can be found in Table 2 and Supplementary Table 1.

Characteristics Associated with Reproducibility

The only studies that were assessed for reproducibility were those that had empirical data. Thus, 115 articles without empirical data were excluded from the initial 294 studies. We also excluded eight case studies and case series because such studies cannot be reproduced. We therefore assessed a total of 171 studies for reproducibility. Of these studies, 163 (95.32%) did not provide a pre-registration statement. Among the 8 studies that provided a pre-registration statement, 4 had accessible links to the pre-registration. Nearly all analyzed studies omitted a data availability statement (162/171, 94.74%). Of the 9 studies that provided a data statement, 2 claimed that their data was not available. None of the 7 studies that claimed their data were available provided enough raw data for the study to be reproduced. Similarly, 156 (96.30%) of 162 analyzed studies (excluding meta-analyses) did not provide a material availability statement. Six studies provided a material availability statement; five of these publications included a statement that materials were available, but only four provided working links to the materials. Only one of the 171 studies included a full protocol in the publication, and none of the 171 studies provided an analysis script availability statement. More characteristics associated with reproducibility are presented in Supplementary Table 1.

Discussion

Our study revealed concerning findings regarding the reproducibility of research in urology literature. Only nine studies made statements regarding the availability of data, and only seven of those actually made their data available. Fewer than half of the studies in our sample were available through Open Access Button, and detailed protocols and pre-registration were rare. One trial in our sample was claimed to be a replication of a previous study, but even this publication failed to include any of the reproducibility markers that we assessed. These findings are similar to those of Hardwicke *et al*[10] for a survey of reproducibility in social sciences.

Our study revealed that only one study contained a link to protocols, while no studies provided analysis scripts and only six provided materials statements. These elements are the three most important ones in reproducing a study. Protocols provide details about how each step of the study was performed, to an extent much deeper than would be relevant to the average person reading the methods section.[13,14] Similarly, analysis scripts are crucial for re-creating the original analysis in a stepwise manner.[15] Materials include anything that was necessary for the study to be performed, including forms, questionnaires, devices, software programs, and more.[16] Some investigators have posited that freely providing these elements invites plagiarism of study design, a major concern with the pressure on researchers to publish while limiting time and funding.[17] Chan *et al*[18] have suggested placing protocols in a lockbox and making them available upon data release to protect intellectual property, while maintaining reproducible research. At the very least, authors should state in their articles that these crucial elements of reproducibility are available upon reasonable request.

Pre-registration is one of the best ways to increase transparency and reproducibility in research, yet only eight studies from our sample were pre-registered. Pre-registration of trials encourages transparency in research by outlining the intended outcomes, interventions, protocols, and methods of analysis before the study is underway.[19] When trials are not pre-registered, investigators have the freedom to manipulate data to obtain significance (P-hacking)[20], hypothesize after results are known (HARKing)[21], switch primary outcomes[22], or deviate from a priori protocols.[23] Several researchers, including Nosek *et al*[24] have called for widespread adoption of pre-registration, citing its value in increasing transparency, rigor, and reproducibility. Early results of pre-registration are positive, with pre-registered studies exhibiting a significant increase in null findings.[25] The OSF hosts pre-registration free of charge and also provides pre-registration templates and instructional guides.[26,27] High-impact journals could require pre-registration for any study to be considered for publication, which would encourage authors to take the necessary steps to increase the chance of having their research published in a respected journal.

Data availability is another area in which urology research falls short. Some journals, including *European Urology*, have begun to require that authors' manuscripts include a description of how readers can access underlying data, while other journals mandate the inclusion of study protocols, analysis scripts, and any other element needed to replicate the original study.[28,29] Beginning in 2019, the International Committee of Medical Journal Editors (ICMJE) mandated data sharing statements by all prospective clinical trials submitted for publication to an ICMJE member journal.[30] Showing that such policies can be successful, *PLoS One*, another journal requiring data availability, reported that 20% of studies published in the journal hosted their data

on a third-party website, 60% provided their data in a supplement, and the remaining 20% made their data available upon reasonable request.[31] These initiatives are steps in the right direction, and we propose a few more possibilities for improving reproducibility in urology research.

The Repeat framework was designed by McIntosh *et al*[32] to improve reproducibility in research. This easy-to-use checklist can be adapted for most studies. Additionally, the OSF developed the Transparency and Openness Promotion (TOP) Guidelines, which provide eight modular standards designed to increase transparency, disclosure, openness, and collaboration.[33] The EQUATOR network has set out to improve research reporting and manuscript writing through the use of reporting guidelines.[34,35] These guidelines, available for nearly every type of study, ensure that manuscripts are written in a transparent way, encouraging reproducibility and accurate reporting of findings.[12] Some journals have begun to require the use of reporting guidelines in the studies they publish.[36–38]

Our study has both strengths and limitations. Regarding strengths, we applied double data extraction procedures, which is considered a best practice methodology by the systematic review community and is recommended in the *Cochrane Handbook for Systematic Reviews of Interventions*. [44] To foster study reproducibility and transparency, we have made all relevant study materials publicly available on OSF. Concerning limitations, our study is cross-sectional in nature, including only PubMed-indexed journals that were published in English during a finite time period. Thus, our results should be interpreted in light of these considerations. Additionally, many replication studies are not published because they are never submitted for publication.[2] In recent years, some organizations, including Elsevier, have encouraged the submission and

publication of replication studies, but they are not yet common in biomedical literature.[45] We did not attempt to contact authors for data availability, analysis scripts, protocols, or any of the other markers of reproducibility. While we may have found these things to be readily available, it is more likely that we would have run up against the familiar issues of low response rate and limited cooperation.[46,47]

Conclusion

Current urology research does not consistently provide the components needed to reproduce original studies. Collaborative efforts from investigators and journal editors are needed to improve research quality, while minimizing waste and patient risk.

References

1. Begley CG, Glenn Begley C, Ioannidis JPA. Reproducibility in Science [Internet]. Vol. 116, Circulation Research. 2015. p. 116–26. Available from: <http://dx.doi.org/10.1161/circresaha.114.303819>
2. Baker M. Is there a reproducibility crisis? A Nature survey lifts the lid on how researchers view the 'crisis rocking science and what they think will help. Nature. 2016;533(7604):452–5.
3. Eisner DA. Reproducibility of science: Fraud, impact factors and carelessness. J Mol Cell Cardiol. 2018 Jan;114:364–8.
4. Loscalzo J. Irreproducible experimental results: causes, (mis)interpretations, and consequences. Circulation. 2012 Mar 13;125(10):1211–4.
5. Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, et al. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. Asian J Urol. 2019 Jan;6(1):10–25.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215–24.
7. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res . 2008 Aug;1(3):174–81.
8. Shepherd BE, Redman MW, Ankerst DP. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc. 2008 Dec 1;103(484):1392–404.
9. Baker SG, Darke AK, Pinsky P, Parnes HL, Kramer BS. Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics. 2010 Jul;11(3):413–8.
10. Hardwicke TE, Wallach JD, Kidwell M, Ioannidis J. An empirical assessment of transparency and reproducibility-related research practices in the social sciences (2014-2017) [Internet]. 2019. Available from: <http://dx.doi.org/10.31222/osf.io/6uhg5>
11. eCFR — Code of Federal Regulations [Internet]. [cited 2019 Jun 27]. Available from: <https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML>
12. Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017 Aug;22(4):139–42.
13. Jirge PR. Preparing and Publishing a Scientific Manuscript. J Hum Reprod Sci. 2017 Jan;10(1):3–9.
14. Jundi AA, Al Jundi A. Protocol Writing in Clinical Research [Internet]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2016. Available from: <http://dx.doi.org/10.7860/jcdr/2016/21426.8865>
15. Piccolo SR, Frampton MB. Tools and techniques for computational reproducibility. Gigascience. 2016 Jul 11;5(1):30.

16. Reddy P, Bhadauria U. Integral elements of a research protocol [Internet]. Vol. 31, Journal of Indian Academy of Oral Medicine and Radiology. 2019. p. 167. Available from: http://dx.doi.org/10.4103/jiaomr.jiaomr_220_18
17. Ross S, Magee L, Walker M, Wood S. Protecting intellectual property associated with Canadian academic clinical trials--approaches and impact. *Trials*. 2012 Dec 27;13:243.
18. Chan A-W, Hróbjartsson A. Promoting public access to clinical trial protocols: challenges and recommendations. *Trials*. 2018 Feb 17;19(1):116.
19. Mistler S. Planning your analyses: Advice for avoiding analysis problems in your research. *Psychological Science Agenda*. 2012;26(11).
20. Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. *Psychol Sci*. 2011 Nov;22(11):1359–66.
21. Kerr NL. HARKing: hypothesizing after the results are known. *Pers Soc Psychol Rev*. 1998;2(3):196–217.
22. Howard B, Scott JT, Blubaugh M, Roepke B, Scheckel C, Vassar M. Systematic review: Outcome reporting bias is a problem in high impact factor neurology journals. *PLoS One*. 2017 Jul 20;12(7):e0180986.
23. Ghooi RB, Bhosale N, Wadhwani R, Divate P, Divate U. Assessment and classification of protocol deviations. *Perspect Clin Res*. 2016 Jul;7(3):132–6.
24. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. *Proc Natl Acad Sci U S A*. 2018 Mar 13;115(11):2600–6.
25. Allen C, Mehler DMA. Open science challenges, benefits and tips in early career and beyond. *PLoS Biol*. 2019 May;17(5):e3000246.
26. OSF [Internet]. [cited 2019 Jul 12]. Available from: <https://osf.io/>
27. Templates of OSF Registration Forms. 2016 Oct 31 [cited 2019 Jul 18]; Available from: <https://osf.io/zab38/wiki/home/>
28. Myers MG Jr, Diabetes Editorial Team. Diabetes Takes New Steps to Increase Transparency and Reproducibility. *Diabetes*. 2019 Apr;68(4):681–2.
29. Guide for Authors: European Urology.
30. Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors [Internet]. Vol. 376, New England Journal of Medicine. 2017. p. 2277–9. Available from: <http://dx.doi.org/10.1056/nejme1705439>
31. 0000-0003-1953-, 0000-0002-7378-. Making Progress Toward Open Data: Reflections on Data Sharing at PLOS ONE | EveryONE: The PLOS ONE blog [Internet]. EveryONE. 2017 [cited 2019 Jul 16]. Available from: <https://blogs.plos.org/everyone/2017/05/08/making-progress-toward-open-data/>

32. McIntosh LD, Juehne A, Vitale CRH, Liu X, Alcoser R, Lukas JC, et al. Repeat: a framework to assess empirical reproducibility in biomedical research. *BMC Med Res Methodol*. 2017 Sep 18;17(1):143.
33. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman SD, Breckler SJ, et al. Transparency and Openness Promotion (TOP) Guidelines [Internet]. 2016. Available from: <http://dx.doi.org/10.1126/science.aab2374>
34. Carpenter CR, Meisel ZF. Overcoming the Tower of Babel in Medical Science by Finding the “EQUATOR”: Research Reporting Guidelines. *Acad Emerg Med* [Internet]. 2017 May 11; Available from: <http://dx.doi.org/10.1111/acem.13225>
35. The EQUATOR Network | Enhancing the QUALity and Transparency Of Health Research [Internet]. [cited 2017 Jun 16]. Available from: <http://www.equator-network.org/>
36. Jorski A, Scott J, Heavener T, Vassar M. Reporting guideline and clinical trial registration requirements in gastroenterology and hepatology journals. *Int J Evid Based Healthc*. 2018 Jun;16(2):119–27.
37. Sims MT, Bowers AM, Fernan JM, Dormire KD, Herrington JM, Vassar M. Trial registration and adherence to reporting guidelines in cardiovascular journals. *Heart*. 2018 May;104(9):753–9.
38. Sims MT, Henning NM, Wayant CC, Vassar M. Do emergency medicine journals promote trial registration and adherence to reporting guidelines? A survey of “Instructions for Authors.” *Scand J Trauma Resusc Emerg Med*. 2016 Nov 24;24(1):137.
39. Wan J, Cain MP, Tanaka S, Nelson C. Conflict of Interest, Self-Reporting and Our Profession. *J Urol*. 2019 Apr;201(4):678–9.
40. Carlisle A, Bowers A, Wayant C, Meyer C, Vassar M. Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines. *Eur Urol*. 2018 Sep;74(3):348–54.
41. Jimbo M, Granberg CF, Osumah TS, Bandari J, Cannon GM, Routh JC, et al. Discrepancies in Self-Reported and Actual Conflicts of Interest for Robotic Pediatric Urological Surgery. *J Urol*. 2019 Feb;201(2):393–9.
42. Lotbiniere-Bassett MP de, de Lotbiniere-Bassett MP, Riva-Cambrin J, McDonald PJ. Conflict of interest policies and disclosure requirements in neurosurgical journals [Internet]. Vol. 131, *Journal of Neurosurgery*. 2019. p. 264–70. Available from: <http://dx.doi.org/10.3171/2018.4.jns172751>
43. Shawwa K, Kallas R, Koujanian S, Agarwal A, Neumann I, Alexander P, et al. Requirements of Clinical Journals for Authors’ Disclosure of Financial and Non-Financial Conflicts of Interest: A Cross Sectional Study [Internet]. Vol. 11, *PLOS ONE*. 2016. p. e0152301. Available from: <http://dx.doi.org/10.1371/journal.pone.0152301>
44. Green S, Higgins J, Alderson P, Clarke M, Mulrow CD, Oxman AD, et al. *Cochrane handbook for systematic reviews of interventions*. West Sussex, England: John Wiley & Sons Ltd [Internet]. 2008; Available from: <http://librariesbegan.info/cochrane-handbook-for-systematic-reviews-of-interventions-to-spread-book-julian-p-t-higgins-sally-green-cochrane-collaboration.pdf>
45. Elsevier, Hylke Koers Phd And. New article type verifies experimental reproducibility [Internet]. Elsevier Connect. 2016 [cited 2019 Jul 17]. Available from: <https://www.elsevier.com/connect/new->

article-type-verifies-experimental-reproducibility

46. Vines TH, Albert AYK, Andrew RL, Débarre F, Bock DG, Franklin MT, et al. The availability of research data declines rapidly with article age. *Curr Biol*. 2014 Jan 6;24(1):94–7.
47. Hardwicke TE, Ioannidis JPA. Populating the Data Ark: An attempt to retrieve, preserve, and liberate data from the most highly-cited psychology and psychiatry articles. *PLoS One*. 2018 Aug 2;13(8):e0201856.

383 Figure 1: Flow Diagram of Included and Excluded Studies for the Reproducibility Analysis

385 **Table 1:** Types of Characteristics Associated with Reproducibility. Sample Sizes (N) depend on
386 study type. Protocol about our measured characteristics is found online. (<https://osf.io/x24n3/>)

<i>Reproducibility Markers</i>		<i>The Importance of Each Marker in Regards with Transparency and Reproducibility.</i>
Accessibility		
All (N=300)	Article accessibility (Is the article available to the public without a paywall?)	Accessible research allows for a larger audience to assess and replicate a study's findings.
Funding		
Included studies (N=294)	Funding statement (Do authors provide a statement to describe if or how the study was funded?)	Including a funding statement provides greater transparency to readers. This increased transparency reveals any signs of bias or influence in the study's methodology.
Conflict of Interest		
Included studies (N=294)	Conflict of interest statement (Do the authors reveal any conflicts of interest in their manuscript?)	Conflict of interest statements give the authors a chance to be transparent about relationships with entities that may try to influence a study's findings.
Publication Citations		
Empirical studies† (N=171)	Systematic review/meta-analysis citations (Has the study been cited by data synthesis study designs such as systematic reviews or meta-analyses?)	Systematic reviews and meta-analyses synthesize information in studies that may have been replicated. The synthesis of information reveals a more complete answer to the question being investigated .
Analysis Scripts		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing the accessibility of the analysis script?)	Having the analysis script allows raw data to be analyzed exactly as the authors did in the original study, allowing others to replicate the data analysis correctly.
	Location of Analysis Script (Where can the analysis script be found? ie. supplementary material)	
	Accessibility (Can a reader access the analysis script through the manuscript online or through other methods?)	

Materials		
Empirical studies¶ (N=162)	Availability statement (Is there a statement in the manuscript describing the accessibility of additional materials to the study?)	Additional materials allows readers to learn what is needed to reproduce the study, enabling the study to be replicated.
	Location of additional materials (Where can the additional material be found? ie. supplementary materials?)	
	Accessibility (Can a reader access additional material through the manuscript online or through other methods?)	
Pre-registration		
Empirical studies‡ (N=138)	Availability statement (Is there a statement in the manuscript describing whether the study was pre-registered or not?)	Pre-registering a study prevents any tampering of the study design throughout implementation of the study, increasing the reliability of the study. Also, pre-registration can provide components that may aid in replicating a study.
	Location of registration(Where was the study registered?)	
	Accessibility of the registration (Is the registration accessible?)	
	Components included in registration (What components of the study were found in the registration?)	
Protocols		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing whether the study protocol was available or not?)	Access to a detailed protocol allows others to know what, where, why, and how the study was performed, aiding others in the replication of the original study.
	Components (What components of the study were found in the protocol?)	
Raw Data		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing the accessibility of raw data from the study?)	Raw data provides insight into the author’s thoughts and actions throughout implementation of the study, aiding others in replication of the original study. Additionally, raw data provides transparency to what is presented in the study’s findings.
	Method of availability (Where can the raw data be found? ie. supplementary materials?)	

	<p>Accessibility (Can a reader access raw data through the manuscript online or through other methods?)</p> <p>Components (Are all the components of raw data that is needed to replicate the study available?)</p> <p>Clarity (Is the raw data understandable?)</p>	
<p>† Empirical studies are studies with empirical data such as: clinical trial, cohort, case series, case reports, case-control, secondary analysis, chart review, commentaries (with data analysis), laboratory, and cross-sectional designs.</p> <p>‡ Empirical studies that are case reports, case series, or studies without World of Science access were excluded from the reproducibility analysis (materials, data, protocol, and registration were excluded) as recommended by Hardwick et al[10].</p> <p>¶ Empirical studies that are either case reports, case series, commentaries with analysis, meta-analyses, or systematic reviews were excluded as they are not expected to provide additional materials.</p>		

387

388

389

390

391

392

393

394

Table 2: Characteristics of Included Publications		
Characteristics		Variables
		N (%)
Funding (N=294)	University	4 (1.36%)
	Hospital	1 (0.34%)
	Public	23 (7.82%)
	Private/Industry	20 (6.80%)
	Non-Profit	2 (0.68%)
	Mixed	28 (9.52%)
	No Statement Listed	185 (62.93%)
	No Funding Received	31 (10.54%)
Type of Study (N=294)	No Empirical Data	115 (39.12%)
	Meta-Analysis	9 (3.06%)
	Chart Review	10 (0.34%)
	Clinical Trial	22 (7.48%)
	Case Study	6 (2.04%)
	Case Series	2 (0.68%)
	Cohort	94 (31.97%)
	Case Control	2 (0.68%)
	Survey	8 (2.72%)
	Laboratory	17 (5.78%)
	Other	9 (3.06%)
5 Year Impact Factor (N=274)	Median	2.466
	1st Quartile	1.898
	3rd Quartile	4.925
	Interquartile Range	1.898 - 4.925

395

396

397

Supplemental 1: Additional Characteristics of Reproducibility in Urology Studies			
Characteristics		Variables	
		N (%)	95% CI
Conflict of Interest Statement (N=294)	Statement, one or more conflicts of interest	36 (12.24%)	8.54 - 15.95
	Statement. no conflict of interest	163 (55.44%)	49.82 - 61.07
	No conflict of interest statement	95 (32.31%)	27.02 - 37.61
Data Availability (N=171)	Statement, some data are available	7 (4.09%)	1.85 - 6.34
	Statement, data are not available	2 (1.17%)	0 - 2.39
	No data availability statement	162 (94.74%)	92.21 - 97.26
Material Availability (N=162)	Statement, some materials are available	5 (3.09%)	1.13 - 5.04
	Statement, materials are not available	1 (0.62%)	0 - 1.50
	No materials availability statement	156 (96.30%)	94.16 - 98.43
Protocol Availability (N=171)	Full Protocol	1 (0.58%)	0 - 1.45
	No Protocol	170 (99.42%)	98.55- 100
Analysis Scripts (N= 171)	Statement, some analysis scripts area vailable	0 (0%)	-
	Statement, analysis scripts are not available	0 (0%)	-
	No analysis script availability statement	171 (100%)	-
Replication Studies (N= 171)	Novel study	170 (99.42%)	98.55 - 100
	Replication	1 (0.58%)	0 - 1.45
Open Access (N= 300)	Yes - found via Open Access Button	87 (29.00%)	23.87 - 34.13

	Yes - found article via other means	1 (0.33%)	0 - 0.99
	Could not access through paywall	212 (70.67%)	65.51 - 75.82
Cited in Systematic Review/ Meta-Analysis (a) (N=169)	No Citations	140 (82.84%)	78.57 - 87.11
	A Single Citation	20 (11.83%)	8.18 - 15.49
	One to Five Citations	9 (5.33%)	2.78 - 7.87
Abbreviations: CI, Confidence Interval. a - No studies were explicitly excluded from the systematic reviews or meta-analyses that cited the original article.			
Pre-Registration (N= 171)	Statement, says was pre--registered	8 (4.68%)	2.29 - 7.07
	Statement, says was not pre-registered	0	-
	No, there is no pre-registration statement	163 (95.32%)	92.93 - 97.71
Test Subjects (N= 294)	Animals	11 (3.74%)	-
	Humans	204 (69.39%)	-
	Neither	79 (26.87%)	-
Country of Journal Publication (N=294)	US	182 (61.90%)	-
	UK	34 (11.56%)	-
	Germany	2 (0.68%)	-
	India	11 (3.74%)	-
	Italy	3 (1.02%)	-
	Unclear	9 (3.06%)	-
	Other (a)	53 (18.03)	-
Country of Corresponding Author (N=294)	US	116 (39.46%)	-
	China	20 (6.80%)	-
	UK	14 (4.76%)	-
	Germany	10 (3.40%)	-
	Japan	13 (4.42%)	-

	France	6 (2.04%)	-
	Canada	14 (4.76%)	-
	Italy	24 (8.16%)	-
	India	2 (0.68%)	-
	Spain	5 (1.70%)	-
	Unclear	11 (3.74%)	-
	Other	59 (17.69%)	-

399

Supplemental 2: Additional Characteristics of Reproducibility in Urology Studies		
Characteristics		Variables
		N (%)
Material Availability (N=162)	Personal or institutional	0
	Supplementary information hosted by the journal	5
	Online third party	0
	Upon Request	0
	Yes, material was accessible	4
	No, material was not accessible	1
Data Availability (N=171)	Personal or institutional	0
	Supplementary journal information	7
	Online third party	0
	Upon Request	0
	Other (b)	0
	Yes, data could be accessed and downloaded	3
	No, data could not be accessed and downloaded	4
	Yes, data files were clearly documented	2
	No, data files were not clearly documented	1

	Yes, data files contain all raw data	0
	No, data files do not contain all raw data	3
	Unclear if all raw data was available	0
Pre-Registration (N=171)	Pre-registered on ClinicalTrials.gov	1
	Other (c)	7
	Yes, pre-registration was accessible	4
	No, pre-registration was not accessible	4
	Hypothesis was pre-registered	2
	Methods were pre-registered	1
	Analysis plan was pre-registered	0
Protocol (N=171)	Hypotheses was included in the protocol	0
	Methods were included in the protocol	0
	Analysis plan was included in the protocol	0